One shot to lower blood pressure? early trial begins

NCT ID NCT07614308

Ongoing Disease control Sponsor: Arnatar Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a single injection of ART101 in 16 adults with high blood pressure. The goal is to see if it is safe and how it affects blood pressure over 24 weeks. Participants receive either 600 mg or 800 mg of the drug and are closely monitored.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ART101 injection

What this could lead to

If successful, this could point toward a new injectable treatment for high blood pressure that requires only a single dose.

What could go wrong

This is a very early Phase 1 trial with only 16 people, so safety and effectiveness are not yet proven. The treatment may not lower blood pressure enough or could cause unexpected side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential hypertension hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTENSION (HTN)

Contacts and locations

Show contact details

Locations

Suzhou Arnatar Therapeutics Co., Ltd

Suzhou, Jiangsu, China